Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis

References

• Lip GYH, Collet J-P, Haude M, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European heart rhythm association (EHRA), European society of cardiology working group on thrombosis, European association of percutaneous cardiovascular interventions (EAPCI), and European association of acute cardiac care (ACCA) endorsed by the heart rhythm society (HRS), Asia-Pacific heart rhythm society (APHRS), Latin America heart rhythm society (LAHRS), and cardiac arrhythmia society of Southern Africa (CASSA).. Europace. 2019;21(2):192–193.
   PubMed Web of Science ®Google Scholar
• Vitolo M, Proietti M, Harrison S, et al. The euro heart survey and EURObservational research programme (EORP) in atrial fibrillation registries: contribution to epidemiology, clinical management and therapy of atrial fibrillation patients over the last 20 years. Intern Emerg Med. 2020 Jun 15. DOI:https://doi.org/10.1007/s11739-020-02405-0
   Google Scholar
• Bang CN, Gislason GH, Greve AM, et al. New-onset atrial fibrillation is associated with cardiovascular events leading to death in a first time myocardial infarction population of 89,703 patients with long-term follow-up: a nationwide study. J Am Heart Assoc. 2014;3(1):e000382.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Huber K, Mehran R, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI: JACC state-of-the-art review. J Am Coll Cardiol. 2019;74(1):83–99.
   PubMed Web of Science ®Google Scholar
• Lip G, Freedman B, De Caterina R, et al. Stroke prevention in atrial fibrillation: past, present and future. Comparing the guidelines and practical decision-making. Thromb Haemost. 2017;117(7):1230–1239.
   PubMed Web of Science ®Google Scholar
• Boriani G, Proietti M, Laroche C, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational research programme on atrial fibrillation (EORP-AF) long-term general registry. Europace. 2018;20(5):747–757.
   PubMed Web of Science ®Google Scholar
• Bernard A, Fauchier L, Pellegrin C, et al. Anticoagulation in patients with atrial fibrillation undergoing coronary stent implantation. Thromb Haemost. 2013;110(3):560–568.
   PubMed Web of Science ®Google Scholar
• Weitz JI, Harenberg J. New developments in anticoagulants: past, present and future. Thromb Haemost. 2017;117(7):1283–1288.
   PubMed Web of Science ®Google Scholar
• Boriani G, Imberti JF, Vitolo M. From meta-analysis to the individual patient with atrial fibrillation and coronary artery disease: the complexity of antithrombotic treatment in real-world clinical practice and the need for a tailored approach. Eur J Intern Med. 2020;77:27–29.
   PubMed Web of Science ®Google Scholar
• van Rein N, Heide-Jørgensen U, Lijfering WM, et al. Major bleeding rates in atrial fibrillation patients on single, dual, or triple antithrombotic therapy. Circulation. 2019;139(6):775–786.
   PubMed Web of Science ®Google Scholar
• Clarke A, Ibrahim A, Kiernan TJ. Triple antithrombotic therapy in patients with atrial fibrillation undergoing PCI: current evidence and practice. Expert Rev Cardiovasc Ther. 2018;16(10):715–723.
   PubMed Web of Science ®Google Scholar
• Kozieł M, Potpara TS, Lip GYH. Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting. Res Pract Thromb Haemost. 2020;4(3):357–365.
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;39(16):1330–1393.
   PubMed Web of Science ®Google Scholar
• Lane DA, Dagres N, Dan GA, et al. Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European heart rhythm association survey. Europace. 2019;21(7):1116–1125.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121–1201.
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European society of cardiology (ESC) and of the European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2018;39(3):213–260.
   PubMed Web of Science ®Google Scholar
• Sibbing D, Angiolillo DJ, Huber K. Antithrombotic therapy for acute coronary syndrome: past, present and future. Thromb Haemost. 2017;117(7):1240–1248.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Mehran R, Bode C, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375(25):2423–2434.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017;377(16):1513–1524.
   PubMed Web of Science ®Google Scholar
• Lopes RD, Heizer G, Aronson R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in Atrial Fibrillation. N Engl J Med. 2019;380(16):1509–1524.
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet. 2019;394(10206):1335–1343.
   PubMed Web of Science ®Google Scholar
• Gopalakrishnan M, Lotfi AS. Stent Thrombosis. Semin Thromb Hemost. 2018;44(1):46–51.
   PubMed Web of Science ®Google Scholar
• Kiviniemi T, Puurunen M, Schlitt A, et al. Bare-metal vs. drug-eluting stents in patients with atrial fibrillation undergoing percutaneous coronary intervention. Circ J. 2014;78(11):2674–2681.
   PubMed Web of Science ®Google Scholar
• Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126–2130.
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Feldman DN, Wang TY, et al. Clinical presentation, management, and outcomes of angiographically documented early, late, and very late stent thrombosis. JACC Cardiovasc Interv. 2012;5(2):131–140.
   PubMed Web of Science ®Google Scholar
• Lüscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation. 2007;115(8):1051–1058.
   PubMed Web of Science ®Google Scholar
• Schulz S, Schuster T, Mehilli J, et al. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur Heart J. 2009;30(22):2714–2721.
   PubMed Web of Science ®Google Scholar
• Tada T, Byrne RA, Simunovic I, et al. Risk of stent thrombosis among bare-metal stents, first-generation drug-eluting stents, and second-generation drug-eluting stents: results from a registry of 18,334 patients. JACC Cardiovasc Interv. 2013;6(12):1267–1274.
   PubMed Web of Science ®Google Scholar
• Stone GW, Witzenbichler B, Weisz G, et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382(9892):614–623.
   PubMed Web of Science ®Google Scholar
• Philip F, Stewart S, Southard JA. Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: network meta-analysis of randomized primary percutaneous coronary intervention trials. Catheter Cardiovasc Interv. 2016;88(1):38–48.
   PubMed Web of Science ®Google Scholar
• Fauchier L, Pellegrin C, Bernard A, et al. Comparison of frequency of major adverse events in patients with atrial fibrillation receiving bare-metal versus drug-eluting stents in their coronary arteries. Am J Cardiol. 2012;110(1):7–12.
   PubMed Web of Science ®Google Scholar
• Limeres J, Lip GYH, Del Blanco BG, et al. Safety of drug-eluting stents compared to bare metal stents in patients with an indication for long-term oral anticoagulation: A propensity score matched analysis. Thromb Res. 2019;177:180–186.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115(17):2344–2351.
   PubMed Web of Science ®Google Scholar
• Garcia-Garcia HM, McFadden EP, Farb A, et al. Standardized end point definitions for coronary intervention trials: the academic research consortium-2 consensus document. Circulation. 2018;137(24):2635–2650.
   PubMed Web of Science ®Google Scholar
• Dangas GD, Claessen BE, Mehran R, et al. Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. JACC Cardiovasc Interv. 2012;5(11):1097–1105.
   PubMed Web of Science ®Google Scholar
• Gori T, Polimeni A, Indolfi C, et al. Predictors of stent thrombosis and their implications for clinical practice. Nat Rev Cardiol. 2019;16(4):243–256.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the american college of cardiology/American heart association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery. Circulation. 2016;134(10):e123–155.
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. Jama. 2019;321(24):2414–2427.
   PubMed Web of Science ®Google Scholar
• Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903–1912.
   PubMed Web of Science ®Google Scholar
• Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010;170(16):1433–1441.
   PubMed Web of Science ®Google Scholar
• Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012;126(10):1185–1193.
   PubMed Web of Science ®Google Scholar
• Dewilde WJ, Oirbans T, Verheugt FW, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381(9872):1107–1115.
   PubMed Web of Science ®Google Scholar
• Fiedler KA, Maeng M, Mehilli J, et al. Duration of triple therapy in patients requiring oral anticoagulation after drug-eluting stent implantation: the ISAR-TRIPLE trial. J Am Coll Cardiol. 2015;65(16):1619–1629.
   PubMed Web of Science ®Google Scholar
• Lopes RD, Leonardi S, Wojdyla DM, et al. Stent thrombosis in patients with atrial fibrillation undergoing coronary stenting in the AUGUSTUS trial. Circulation. 2020;141(9):781–783.
   PubMed Web of Science ®Google Scholar
• Alexander JH, Wojdyla D, Vora AN, et al. The risk/benefit tradeoff of antithrombotic therapy in patients with atrial fibrillation early and late after an acute coronary syndrome or percutaneous coronary intervention: insights from AUGUSTUS. Circulation. 2020;141(20):1618–1627.
   Google Scholar
• Golwala HB, Cannon CP, Steg PG, et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018;39(19):1726–1735a.
   PubMed Web of Science ®Google Scholar
• Potpara TS, Mujovic N, Proietti M, et al. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Europace. 2020;22(1):33–46.
   PubMed Web of Science ®Google Scholar
• Gargiulo G, Goette A, Tijssen J, et al. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J. 2019;40(46):3757–3767.
   PubMed Web of Science ®Google Scholar
• Khan SU, Osman M, Khan MU, et al. Dual versus triple therapy for atrial fibrillation after percutaneous coronary intervention: a systematic review and meta-analysis. Ann Intern Med. 2020;172(7):474–483.
   Web of Science ®Google Scholar
• Galli M, Andreotti F, Porto I, et al. Intracranial haemorrhages vs. stent thromboses with direct oral anticoagulant plus single antiplatelet agent or triple antithrombotic therapy: a meta-analysis of randomized trials in atrial fibrillation and percutaneous coronary intervention/acute coronary syndrome patients. Europace. 2020;22(4):538–546.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–1057.
   PubMed Web of Science ®Google Scholar
• Steg PG, Harrington RA, Emanuelsson H, et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation. 2013;128(10):1055–1065.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.
   PubMed Web of Science ®Google Scholar
• Gimbel M, Qaderdan K, Willemsen L, et al. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet. 2020;395(10233):1374–1381.
   PubMed Web of Science ®Google Scholar
• Oldgren J, Steg PG, Hohnloser SH, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019;40(19):1553–1562.
   PubMed Web of Science ®Google Scholar
• Sarafoff N, Martischnig A, Wealer J, et al. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61(20):2060–2066.
   PubMed Web of Science ®Google Scholar
• Verlinden NJ, Coons JC, Iasella CJ, et al. Triple antithrombotic therapy with aspirin, P2Y12 inhibitor, and warfarin after percutaneous coronary intervention: an evaluation of prasugrel or ticagrelor versus clopidogrel. J Cardiovasc Pharmacol Ther. 2017;22(6):546–551.
   PubMed Web of Science ®Google Scholar
• Lupercio F, Giancaterino S, Villablanca PA, et al. P2Y12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis. Heart. 2020;106(8):575–583.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–2962.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Seivani Y, Abdel-Wahab M, Geist V, et al. Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents. Clin Res Cardiol. 2013;102(11):799–806.
   PubMed Web of Science ®Google Scholar
• Hamon M, Lemesle G, Tricot O, et al. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol. 2014;64(14):1430–1436.
   PubMed Web of Science ®Google Scholar
• Lamberts M, Gislason GH, Lip GY, et al. Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients taking an oral anticoagulant: a nationwide cohort study. Circulation. 2014;129(15):1577–1585.
   PubMed Web of Science ®Google Scholar
• Fischer Q, Georges JL, Le Feuvre C, et al. Optimal long-term antithrombotic treatment of patients with stable coronary artery disease and atrial fibrillation: “OLTAT registry”. Int J Cardiol. 2018;264:64–69.
   PubMed Web of Science ®Google Scholar
• Lemesle G, Ducrocq G, Elbez Y, et al. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: association with ischemic and bleeding events. Clin Cardiol. 2017;40(10):932–939.
   PubMed Web of Science ®Google Scholar
• Patti G, Pecen L, Lucerna M, et al. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. Int J Cardiol. 2018;270:160–166.
   PubMed Web of Science ®Google Scholar
• Lee SR, Rhee TM, Kang DY, et al. Meta-analysis of oral anticoagulant monotherapy as an antithrombotic strategy in patients with stable coronary artery disease and nonvalvular atrial fibrillation. Am J Cardiol. 2019;124(6):879–885.
   PubMed Web of Science ®Google Scholar
• Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-label randomized trial comparing oral anticoagulation with and without single antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stent implantation. Circulation. 2019;139(5):604–616.
   PubMed Web of Science ®Google Scholar
• Yasuda S, Kaikita K, Akao M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. N Engl J Med. 2019;381(12):1103–1113.
   PubMed Web of Science ®Google Scholar
• Xanthopoulou I, Dragona VM, Davlouros P, et al. Contemporary antithrombotic treatment in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: rationale and design of the greek antiplatelet atrial fibrillation (GRAPE-AF) registry. Cardiovasc Drugs Ther. 2018;32(2):191–196.
   PubMed Web of Science ®Google Scholar
• Kalarus Z, Svendsen JH, Capodanno D, et al. Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European heart rhythm association (EHRA) consensus document, endorsed by the European association of percutaneous cardiovascular interventions (EAPCI), and European acute cardiovascular care association (ACCA). Europace. 2019;21(10):1603–1604.
   PubMed Web of Science ®Google Scholar